Global Diabetic Nephropathy Pipeline Assessment, H1 2020: Therapeutics, Developments, Products, Drugs, Players

News provided by

Apr 27, 2020, 08:15 ET

DUBLIN, April 27, 2020 /PRNewswire/ -- The "Diabetic Nephropathy: H1 2020 Pipeline Review" drug pipelines has been added to ResearchAndMarkets.com's offering.

This pipeline guide provides comprehensive information on the therapeutics under development for Diabetic Nephropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Nephropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 20, 16, 27 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 1 molecules, respectively.

Diabetic Nephropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy (Metabolic Disorders).
The pipeline guide reviews pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Diabetic Nephropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Diabetic Nephropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders).

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
Find and recognize significant and varied types of therapeutics under development for Diabetic Nephropathy (Metabolic Disorders).
Classify potential new clients or partners in the target demographic.
Develop tactical initiatives by understanding the focus areas of leading companies.
Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
Formulate corrective measures for pipeline projects by understanding Diabetic Nephropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered

Introduction
Overview
Therapeutics Development
Therapeutics Assessment
Companies Involved in Therapeutics Development
Drug Profiles
Dormant Projects
Discontinued Products
Product Development Milestones
Appendix

Companies Mentioned

Aibios Co Ltd
Algomedix Inc
Allist Shanghai Pharmaceutical Technology Co Ltd
Antisense Therapeutics Ltd
APT Therapeutics Inc
AptaBio Therapeutics Inc
Araim Pharmaceuticals Inc
Astellas Pharma Inc
AstraZeneca Plc
Bayer AG
Betagenon AB
Bird Rock Bio Inc
BLR Bio LLC
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
CCRP Therapeutics GmbH
Cellmid Ltd
Certa Therapeutics Pty Ltd
ChemoCentryx Inc
Corbus Pharmaceuticals Inc
CSL Ltd
cStem Regeneration Pharmaceutical Co Ltd
Curacle Co Ltd
Cyclerion Therapeutics Inc
Daiichi Sankyo Co Ltd
Dimerix Ltd
Future Medicine Co Ltd
GenKyoTex SA
Gilead Sciences Inc
Glycadia Inc
GNI Group Ltd
Goldfinch Biopharma Inc
Guangzhou Magpie Pharmaceutical Co Ltd
Inspyr Therapeutics Inc
Johnson & Johnson
Liminal BioSciences Inc
MediPost Co Ltd
Merck & Co Inc
Mesoblast Ltd
Mitsubishi Tanabe Pharma Corp
Novartis AG
Novo Nordisk AS
Noxxon Pharma AG
Orbsen Therapeutics Ltd
Paranta Biosciences Ltd
PhytoHealth Corp
ProKidney LLC
Reata Pharmaceuticals Inc
Redx Pharma Plc
Sarfez Pharmaceuticals Inc
Scohia Pharma Inc
Serodus ASA
siRNAgen Therapeutics Corp
Sulfateq BV
Teijin Pharma Ltd
Theravance Biopharma Inc
Twoxar Inc
Vidasym Inc
ZyVersa Therapeutics Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/71sx10

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets